Beranda › Mieloma Multipel › Indiana
Uji klinis Mieloma Multipel di Indiana
19 studi untuk Mieloma Multipel mencari peserta di lokasi di Indiana.
Kota di Indiana
Teks studi resmi (Bahasa Inggris)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07582432A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Franciscan Health, Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Indiana University, Indianapolis
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05201781A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Genesis Medical Research, Dyer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07477587A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Fort Wayne Medical Oncology And Hematology /ID# 278141, Fort Wayne
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Indiana University - Purdue, Indianapolis
Menerima pesertaStudi observasional
2 Months · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT00900198MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04566328A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Indiana University, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Indiana University Health, Indianapolis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07284758A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne
- Franciscan St. Francis Health /ID# 280928, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Indiana University Health Simon Cancer Center, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jul 2026 · NCT05137054Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Community Health Network, Indianapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jun 2026 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- dan 8 lainnya
Menerima pesertaFase 3
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT05561387cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881The Indiana Myeloma Registry
- Indiana University Simon Cancer Center, Indianapolis
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Nov 2025 · NCT03616483Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.